Structure Therapeutics Inc
GPCR17.576USD
-0.014-0.08%
交易中 （美東）報價延遲15分鐘
3.03B總市值
虧損本益比TTM
關於 Structure Therapeutics Inc 公司
Structure Therapeutics Inc. 是一家臨牀階段的全球生物製藥公司，致力於開發用於代謝和心肺疾病的新型口服小分子療法。該公司專注於 G 蛋白偶聯受體 (GPCR) 作爲治療靶點類別。其候選產品包括 GSBR-1290、Amylin、葡萄糖依賴性胰島素促泌多肽受體 (GIPR)、GCGR、ANPA-0073 和 LTSE-2578。該公司正在開發 GSBR-1290，這是其口服小分子候選產品，針對經過驗證的胰高血糖素樣肽-1 受體 (GLP-1R)，用於治療 2 型糖尿病 (T2DM) 和肥胖症。該公司正在開發 GLP-1R 候選藥物，包括雙重 GLP-1R/GIPR 激動劑和 Amylin 激動劑，每種藥物都具有定製特性，可實現額外益處。該公司正在開發 ANPA-0073，這是一種在研口服小分子 APJR 激動劑，用於治療特發性肺纖維化 (IPF)。該公司正在評估其 LPA1R 項目 LTSE-2578，用於治療 IPF 和進行性肺纖維化。
公司簡介
公司代碼GPCR
公司名稱Structure Therapeutics Inc
上市日期Feb 03, 2023
CEODr. Raymond Stevens, Ph.D.
員工數量163
證券類型Depository Receipt
年結日Feb 03
公司地址611 Gateway Blvd Suite 223
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94080
電話16282299277
網址https://structuretx.com/
公司代碼GPCR
上市日期Feb 03, 2023
CEODr. Raymond Stevens, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.07K
+1142.70%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
31.82K
+332.50%
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Dr. Joanne Waldstreicher, M.D.
Dr. Joanne Waldstreicher, M.D.
Independent Director
Independent Director
--
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
--
--
Dr. Blai Coll, M.D., Ph.D.
Dr. Blai Coll, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Angus Russell
Mr. Angus Russell
Independent Director
Independent Director
--
--
Dr. Raymond Stevens, Ph.D.
Dr. Raymond Stevens, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.07K
+1142.70%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
31.82K
+332.50%
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Dr. Joanne Waldstreicher, M.D.
Dr. Joanne Waldstreicher, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月9日 週五
更新時間: 5月9日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Wellington Management Company, LLP
13.54%
Fidelity Management & Research Company LLC
10.08%
Janus Henderson Investors
7.57%
Deep Track Capital LP
7.13%
Capital Research Global Investors
3.76%
Other
57.93%
持股股東
持股股東
佔比
Wellington Management Company, LLP
13.54%
Fidelity Management & Research Company LLC
10.08%
Janus Henderson Investors
7.57%
Deep Track Capital LP
7.13%
Capital Research Global Investors
3.76%
Other
57.93%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
38.24%
Investment Advisor
31.60%
Hedge Fund
22.90%
Venture Capital
4.66%
Individual Investor
3.08%
Research Firm
2.11%
Private Equity
1.86%
Pension Fund
0.06%
Bank and Trust
0.03%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
379
60.17M
104.57%
-15.84M
2025Q1
381
62.21M
108.14%
-12.86M
2024Q4
357
66.09M
115.26%
-5.81M
2024Q3
330
65.93M
115.14%
-2.45M
2024Q2
298
63.40M
110.86%
+11.42M
2024Q1
239
45.01M
96.54%
-1.29M
2023Q4
210
43.42M
93.57%
+9.41M
2023Q3
125
33.38M
93.24%
+15.44M
2023Q2
64
17.69M
49.41%
+2.82M
2023Q1
49
14.88M
38.91%
+11.89M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Wellington Management Company, LLP
7.79M
13.54%
+5.57K
+0.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.80M
10.08%
-218.60K
-3.63%
Mar 31, 2025
Janus Henderson Investors
4.36M
7.57%
+195.31K
+4.69%
Mar 31, 2025
Deep Track Capital LP
4.10M
7.13%
+1.10M
+36.67%
Mar 31, 2025
Capital Research Global Investors
2.16M
3.76%
-1.37M
-38.82%
Mar 31, 2025
Vestal Point Capital, LP
1.79M
3.11%
+63.99K
+3.71%
Mar 31, 2025
BVF Partners L.P.
1.77M
3.08%
--
--
Mar 31, 2025
Capital International Investors
1.62M
2.81%
-55.00
-0.00%
Mar 31, 2025
RA Capital Management, LP
1.52M
2.64%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
1.27M
2.21%
-784.67K
-38.14%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Roundhill GLP-1 & Weight Loss ETF
3.88%
TrueShares Technology, AI & Deep Learning ETF
2.57%
Amplify Weight Loss Drug & Treatment ETF
1.86%
WisdomTree BioRevolution Fund
1.24%
Tema Heart & Health ETF
1.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
ALPS Medical Breakthroughs ETF
0.81%
American Century Focused Dynamic Growth ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
查看更多
Roundhill GLP-1 & Weight Loss ETF
佔比3.88%
TrueShares Technology, AI & Deep Learning ETF
佔比2.57%
Amplify Weight Loss Drug & Treatment ETF
佔比1.86%
WisdomTree BioRevolution Fund
佔比1.24%
Tema Heart & Health ETF
佔比1.01%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.84%
ALPS Medical Breakthroughs ETF
佔比0.81%
American Century Focused Dynamic Growth ETF
佔比0.28%
ProShares Ultra Nasdaq Biotechnology
佔比0.14%
Invesco Nasdaq Biotechnology ETF
佔比0.14%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
